MoonLake Immunotherapeutics — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that MoonLake Immunotherapeutics filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($69.73M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($55.22M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($39.94M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($35.39M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($24.27M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($13.67M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($9.43M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($10.14M) | Aug 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($9.00M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($10.11M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($12.12M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($15.88M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($6.29M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($32.69M) | Aug 12, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($76.3K) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($5.0K) | Dec 14, 2021 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($71.43M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($60.70M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($47.49M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($43.11M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($30.58M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($19.82M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($12.98M) | Nov 7, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($13.19M) | Aug 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.93M) | May 7, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($14.77M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($17.65M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($15.94M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($6.27M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($32.68M) | Aug 12, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($94.1K) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($5.0K) | Dec 14, 2021 |